, Volume 45, Issue 4, pp 477–487 | Cite as


Current Experience and Future Directions in Therapy
  • Patrick J. Loehrer
Leading Article


Thymoma Thymic Carcinoma Cancer Treatment Report Thymic Epithelial Tumor Invasive Thymoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arriagada R, Bretel JJ, Caillaud JM, Garreta L, Guerin RA, et al. Invasive carcinoma of the thymus. A multicenter retrospective review of 56 cases. European Journal of Clinical Oncology 20: 69–74, 1984CrossRefGoogle Scholar
  2. Asamura H, Nakajima T, Mukai K, Noguchi M, Shimosato Y, et al. Degree of malignancy of thymic epithelial tumors in terms of nuclear DNA content and nuclear area. An analysis of 39 cases. American Journal of Pathology 133: 615–622, 1988PubMedGoogle Scholar
  3. Batata MA, Martini N, Huvos AG, Aguilar RI, Beattie EJ. Thymomas: clinicopathologic features, therapy, and prognosis. Cancer 34: 389–396, 1974PubMedCrossRefGoogle Scholar
  4. Bergh NP, Gakinsky P, Larsson S, Lundin P, Ridell B. Tumors of the thymus and thymic regions: I. Clinicopathological studies of thymomas. Annals of Thoracic Surgery 25: 91, 1978PubMedCrossRefGoogle Scholar
  5. Bernatz PE, Khonsari S, Harrison EG, Taylor WF. Thymoma: factors influencing prognosis. Surgical Clinics of North America 53: 885–892, 1973PubMedGoogle Scholar
  6. Berthaud P, LeChevalier T, Tursz T. Effectiveness of inter-leukin-2 in invasive lymphoepithelial thymoma. Correspondence. Lancet 335: 1590, 1990PubMedCrossRefGoogle Scholar
  7. Bonomi P, Aisner S, Ettinger D, Finkelstein D. Phase II trial of cisplatin in recurrent or metastatic malignant thymoma: an ECOG trial. Proceedings of the American Society of Clinical Oncology 7: 221, 1988Google Scholar
  8. Boston B. Chemotherapy of invasive thymoma. Cancer 38: 49–52, 1976PubMedCrossRefGoogle Scholar
  9. Butler WM, Diehl LF, Taylor HG, Weltz MD. Metastatic thymoma with myasthenia gravis. Complete remission with combination therapy. Cancer 50: 419–422, 1982PubMedCrossRefGoogle Scholar
  10. Campbell MG, Pollard R, Al-Sarraf M. A complete response in metastatic malignant thymoma to cis-platinum, doxorubicin and cyclophosphamide. Cancer 98: 1315–1317, 1981CrossRefGoogle Scholar
  11. Chahinian AP, Bhardwaj S, Meyer RJ, Jaffrey IS, Kirschner PA, et al. Treatment of invasive or metastatic thymoma. Cancer 47: 1752–1761, 1981PubMedCrossRefGoogle Scholar
  12. Chahinian AP, Nogrire C, Ohnuma T, Greenberg ML, Sivak M, et al. Phase I study of weekly maytansine given by IV bolus or 24-hour infusion. Cancer Treatment Reports 63: 1953–1960, 1979PubMedGoogle Scholar
  13. Chilosi M, Iannucci A, Menestrina F, Lestani M, Scarpa A, et al. Immunohistochemical evidence of active thymocyte proliferation in thymoma. Its possible role in the pathogenesis of autoimmune diseases. American Journal of Pathology 128: 464–470, 1987PubMedGoogle Scholar
  14. Curran WJ, Kornstein MJ, Brooks JJ, Turrissi AT. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. Journal of Clinical Oncology 6: 1722–1727, 1988PubMedGoogle Scholar
  15. Daugaard G, Hanson HH, Rorth M. Combination chemotherapy for malignant thymomas. Annals of Internal Medicine 99: 189–190, 1983PubMedGoogle Scholar
  16. Donovan PJ, Foley JF. Chemotherapy in invasive thymomas: five case reports. Journal of Surgical Oncology (New York) 33: 14–17, 1986Google Scholar
  17. Dy C, Calvo FA, Mindan JP, Aparicio LA, Algarra SM, et al. Undifferentiated epithelial-rich invasive malignant thymoma: complete response to cisplatin, vinblastine, and bleomycin therapy. Journal of Clinical Oncology 6: 536–542, 1988PubMedGoogle Scholar
  18. Fornasiero A, Daniele O, Ghiotto C, Sartori F, Rea F, et al. Chemotherapy of invasive thymoma. Journal of Clinical Oncology 8: 1419, 1423, 1990PubMedGoogle Scholar
  19. Gerein AN, Srivastava SP, Burgess J. Thymoma: a ten year review. American Journal of Surgery 136: 49–53, 1978PubMedCrossRefGoogle Scholar
  20. Goldel N, Boning L, Fredrik A, Hozel D, Hartenstein R, et al. Chemotherapy of invasive thymoma: a retrospective study of 22 cases. Cancer 63: 1493–1500, 1989PubMedCrossRefGoogle Scholar
  21. Harper PG, Highley M, Rankin E, Dussek J, Bryant B, et al. Ifosfamide monotherapy demonstrates high activity in malignant thymoma. Proceedings of the American Society of Clinical Oncology 10: 1049, 1991Google Scholar
  22. Harper P, Addis B. Unusual tumors of the medastinum. In Williams et al. (Eds) Textbook of uncommon cancer, pp. 411–448, John Wiley & Sons, Chichester, 1988Google Scholar
  23. Hu E, Levine J. Chemotherapy of malignant thymoma: case report and review of the literature. Cancer 57: 1101–1104, 1986PubMedCrossRefGoogle Scholar
  24. Jaffrey L. Response to maytansine in a patient with malignant thymoma. Cancer Treatment Reports 64: 193–194, 1980PubMedGoogle Scholar
  25. Klippstein TH, Mitrov PS, Kochendorfer K, Bergmann L. High dose adriamycin and cisplatin in advanced soft tissue sarcomas and invasive thymomas. Cancer Chemotherapy and Pharmacology 13: 78–81, 1984PubMedCrossRefGoogle Scholar
  26. Kornstein MJ, Curran WJ, Turrisi AT, Brooks JJ. Cortical versus medullary thymomas: a useful morphologic distinction?. Human Pathology 19: 1335–1339, 1988PubMedCrossRefGoogle Scholar
  27. Kosmidis PA, Iliopoulos E, Pentea S. Combination chemotherapy with cyclophosphamide, adriamycin, and vincristine in malignant thymoma and myasthenia gravis. Cancer 61: 1736–1740, 1988PubMedCrossRefGoogle Scholar
  28. Lauriola L, Maggiano N, Marino M, Carbone A, Piamtelli M, et al. Human thymoma: immunologic characteristics of the lymphocyte component. Cancer 48: 1992, 1981PubMedCrossRefGoogle Scholar
  29. Legg MA, Brady WJ. Pathology and clinical behaviour of thymomas: a survey of 51 cases. Cancer 18: 1131–1144, 1965PubMedCrossRefGoogle Scholar
  30. Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Taylor WF. Thymoma. A clinicopathologic review. Cancer 60: 2727–2743, 1987PubMedCrossRefGoogle Scholar
  31. Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Annals of Internal Medicine 109: 540–546, 1988PubMedGoogle Scholar
  32. Loehrer PJ, Bonomi P, Goldman S, Reddy S, Faber LP, et al. Remission of invasive thymoma due to chemotherapy. Chest 87: 377–380, 1985PubMedCrossRefGoogle Scholar
  33. Loehrer PJ, Perez CA, Roth LM, Greco FA, Livingston RB, et al. Chemotherapy for advanced thymoma: preliminary results of an intergroup study. Annals of Internal Medicine 113: 520–524, 1990PubMedGoogle Scholar
  34. Macchiarini P, Chella A, Ducci F, Rossi B, Testi C, et al. Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 68: 706–713, 1991PubMedCrossRefGoogle Scholar
  35. Maggi G, Giaccone G, Donadio M, Ciuffreda L, Dalesio O, et al. Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. Cancer 58: 765–776, 1986PubMedCrossRefGoogle Scholar
  36. Marks RD Jr, Wallace KM, Pettit HS. Radiation therapy control of nine patients with malignant thymoma. Cancer 41: 117–119, 1978PubMedCrossRefGoogle Scholar
  37. Masaoka A, Monden Y, Nakahara K, Tamioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485–2492, 1981PubMedCrossRefGoogle Scholar
  38. Masaoka A, Nagaoka Y, Maeda M, Mondem Y, Seike Y, et al. Study on the ratio of lymphocytes to epithelial cells in thymoma. Cancer 40: 1222–1228, 1977PubMedCrossRefGoogle Scholar
  39. Michon JM, Caligiuri MA, Hazanow SM, Levine H, Schloss-man SF, et al. Induction of natural killer effectors form human thymus with recombinant interleukin-2. Journal of Immunology 140: 3660–3667, 1988Google Scholar
  40. Mitrov PS, Bergmann L, Tuengerthal S. Induktion einer Kompletten Remission mit Adriamycin und Cis-Platin bei einem, invasiv wachsenden Thymom. Deutsche Medizinische Wochenschrift 44: 1667, 1982CrossRefGoogle Scholar
  41. Mizuno T, Hashimoto T, Masaoka A. Distribution of fibro-nectin and laminin in human thymoma. Cancer 65: 1267–1374, 1990CrossRefGoogle Scholar
  42. Muller-Hermelink HK, Marino M, Palestro G. Pathology of thymic epithelial tumors. Current Topics in Pathology 75: 207–268, 1986PubMedCrossRefGoogle Scholar
  43. Nabholz M, MacDonald H. Cytolytic T lymphocytes. Annual Review of Immunology 1: 273–306, 1983PubMedCrossRefGoogle Scholar
  44. Nomori H, Ishihara T, Torikata C. Malignant grading of cortical and medullary differentiated thymoma by morphometric analysis. Cancer 64: 1694–1699, 1989PubMedCrossRefGoogle Scholar
  45. Patterson GA. Thymomas. Seminars in Thoracic and Cardiovascular Surgery 4: 39–44, 1992PubMedGoogle Scholar
  46. Penn CRH, Hope-Stone HF. The role of radiotherapy in the management of malignant thymoma. British Journal of Surgery 59: 533–538, 1972PubMedCrossRefGoogle Scholar
  47. Pescarmona E, Rendina EA, Venuta F, Ricci C, Ruco LP, et al. Analysis of prognostic factors and clinicopathological staging of thymoma. Annals of Thoracic Surgery 55: 534–538, 1990CrossRefGoogle Scholar
  48. Phillips J, Lanier L. Acquisition of non-MHC restricted cytotoxic function by IL-2 activated thymocytes with an ‘immature’ antigenic phenotype. Journal of Immunology 139: 638–687, 1987Google Scholar
  49. Pollack A, El-Naggar AK, Cox JD, Ro JY, Sahin A, et al. Thymoma. The prognostic significance of flow cytometric DNA analysis. Cancer 69: 1702–1709, 1992PubMedCrossRefGoogle Scholar
  50. Ribeiro RC, Patton DF, Jenkins J, Sixby JW. Thymic carcinoma with a defective Epstein-Barr virus encoding the BZLF1 trans-activator. Proceedings of the American Society of Clinical Oncology 10: 76, 1991Google Scholar
  51. Rosenberg JC. Neoplasms of the mediastinum. In DeVita et al. (Eds) Cancer principles and practice of oncology, Vol. 1, pp. 706–724, JB Lippincott, Philadelphia, 1989Google Scholar
  52. Rouse RV, Weiss LM. Human thymomas: evidence of im-munohistologically defined normal and abnormal mi-croenvironmental differentiation. Cellular Immunology 111: 94106, 1988CrossRefGoogle Scholar
  53. Stolinsky DC, Hum GJ, Jacobs EM, Solomon J, Bateman JR. Clinical trial of weekly doses of vinblastine (NSC-49842) combined with vincristine (NSC-67574) in malignant lymphoma and other neoplasms. Cancer Chemotherapy Reports 57: 477–484, 1973Google Scholar
  54. Urgeis A, Monetti U, Rossi G, et al. Role of radiation therapy in locally advanced thymoma. Radiotherapy and Oncology 19: 273–280, 1990CrossRefGoogle Scholar
  55. Vematsu M, Kondo M. A proposal for treatment of invasive thymoma. Cancer 58: 1979–1984, 1986CrossRefGoogle Scholar
  56. Wilkins EW, Castleman B. Thymoma: a continuing survey at the Massachusetts General Hospital. Annals of Thoracic Surgery 28: 252–256, 1979PubMedCrossRefGoogle Scholar
  57. Yamakawa Y, Masaoka A, Hashimoto T, Niwa H, Mizuno T, et al. A tentative tumor-node-metastasis classification of thymoma. Cancer 68: 1984–1987, 1991PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Patrick J. Loehrer
    • 1
  1. 1.Department of Medicine, Section of Hematology/OncologyIndiana University Medical CenterIndianapolisUSA

Personalised recommendations